Brief: Iveric Bio Does Not Expect To Initiate Phase 1/2 Clinical Trial For IC-200 In 2021

IVERIC bio

21/10/2021 22:46

Oct 21 (Reuters) - Iveric Bio Inc  ISEE.O :
    * IVERIC BIO INC - DOES NOT NOW EXPECT TO INITIATE A PHASE
1/2
CLINICAL TRIAL FOR IC-200 IN 2021
    * IVERIC BIO - EXPECTS RE-PRIORITIZATION WILL ALLOW IT TO
DEVOTE
ADDITIONAL MONEY TO ZIMURA DEVELOPMENT, PRE-COMMERCIALIZATION
EFFORTS
    * IVERIC BIO INC - PLANS TO SEEK A COLLABORATOR OR LICENSEE
FOR
FUTURE DEVELOPMENT,  POTENTIAL COMMERCIALIZATION OF IC-100 AND
IC-200

Source text for Eikon: [https://bit.ly/3E839FB]
Further company coverage:  ISEE.O 

 ((Reuters.Briefs@thomsonreuters.com;))